The effect of omalizumab on small airway inflammation as measured by exhaled nitric oxide in moderate-to-severe asthmatic patients

Allergy and Asthma Proceedings

Volumn 35, Issue 3, 2014, Pages 241-249

  Pasha, M Asghar ^a   Jourd'Heuil, David ^a   Jourd'Heuil, Francis ^a   Mahon, Lori ^b   Romero, Francisco ^b   Feustel, Paul J ^a   Evans, Mary ^a   Smith, Thomas ^a   Mitchell, Jesse ^b   Gendapodi, Pradeep ^b   DeMeyere Coursey, Kelly C ^b   Townley, Robert G ^b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b CREIGHTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN E; NITRIC OXIDE; OMALIZUMAB; PLACEBO; ANTIASTHMATIC AGENT; ANTIIDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY;

ADD ON THERAPY; ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EXPIRED AIR; HUMAN; LUNG FUNCTION TEST; LUNG GAS EXCHANGE; MEASUREMENT; MODERATE PERSISTENT ASTHMA; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFLAMMATION; SKIN TEST; ASTHMA; CLINICAL TRIAL; EXHALATION; FEMALE; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; EXHALATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; SKIN TESTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84899816592     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2014.35.3741     Document Type: Article

References (49)

1. Bellamy D, and Harris T. Poor perceptions and expectations of asthma control: Results of the International Control of Asthma Symptoms (ICAS) survey of patients and general practitioners. Prim Care Respir J 14:252-258, 2005. (Pubitemid 41436410)
2. Carlton BG, Lucas DO, Ellis EF, et al. The status of asthma control and asthma prescribing practices in the United States: Results of a large prospective asthma control survey of primary care practices. J Asthma 42:529 -535, 2005.
3. Rabe KF, Vermeire PA, Soriano JB, et al. Clinical management of asthma in 1999: The Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 16:802- 807, 2000.
4. Leach CL. Improved delivery of inhaled steroids to the large and small airways. Respir Med 92(suppl A):3- 8, 1998.
5. Berry M, Hargadon B, Morgan A, et al. Alveolar nitric oxide in adults with asthma: Evidence of distal lung inflammation in refractory asthma. Eur Respir J 25:986 -991, 2005.
6. Brindicci C, Ito K, Barnes PJ, and Kharitonov SA. Differential flow analysis of exhaled nitric oxide in patients with asthma of differing severity. Chest 131:1353-1362, 2007. (Pubitemid 46762339)
7. Alving K, Weitzberg E, and Lundberg JM. Increased amount of nitric oxide in exhaled air of asthmatics. Eur Respir J 6:1368-1370, 1993. (Pubitemid 23329557)
8. Kharitonov SA, Yates D, Robbins RA, et al. Increased nitric oxide in exhaled air of asthmatic patients. Lancet 343:133-135, 1994. (Pubitemid 24028638)
9. Taylor DR, Pijnenburg MW, Smith AD, and De Jongste JC. Exhaled nitric oxide measurements: Clinical application and interpretation. Thorax 61:817- 827, 2006.
10. Kharitonov SA, and Barnes PJ. Nitric oxide in exhaled air is a new marker of airway inflammation. Monaldi Arch Chest Dis 51:533-537, 1996. (Pubitemid 27076048)
11. Payne DN, Adcock IM, Wilson NM, et al. Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in children with difficult asthma, after treatment with oral prednisolone. Am J Respir Crit Care Med 164:1376 -1381, 2001.
12. Warke TJ, Fitch PS, Brown V, et al. Exhaled nitric oxide correlates with airway eosinophils in childhood asthma. Thorax 57:383-387, 2002. (Pubitemid 34494145)
13. Bukstein D, Luskin AT, and Brooks EA. Exhaled nitric oxide as a tool in managing and monitoring difficult-to-treat asthma. Allergy Asthma Proc 32:185-192, 2011.
14. Mahr TA, Malka J, and Spahn JD. Inflammometry in pediatric asthma: A review of fractional exhaled nitric oxide in clinical practice. Allergy Asthma Proc 34:210 -219, 2013.
15. Alving K, and Malinovschi A. Basic aspects of exhaled nitric oxide. In Exhaled Biomarkers. Horvath I and de Jongste J (Eds). Maney Publishing Inc, Leeds, UK. Vol.49, 1-31, 2013.
16. American Thoracic Society; European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 171:912-930, 2005.
17. George SC, Hogman M, Permutt S, and Silkoff PE. Modeling pulmonary nitric oxide exchange. J Appl Physiol 96:831- 839, 2004.
18. Högman M, Holmkvist T, Wegener T, et al. Extended NO analysis applied to patients with COPD, allergic asthma and allergic rhinitis. Respir Med 96:24 -30, 2002.
19. Pietropaoli AP, Perillo IB, Torres A, et al. Simultaneous measurement of nitric oxide production by conducting and alveolar airways of humans. J Appl Physiol 87:1532-1542, 1999. (Pubitemid 29483144)
20. Silkoff PE, Sylvester JT, Zamel N, and Permutt S. Airway nitric oxide diffusion in asthma: Role in pulmonary function and bronchial responsiveness. Am J Respir Crit Care Med 161:1218-1228, 2000. (Pubitemid 30243833)
21. Tsoukias NM, and George SC. A two-compartment model of pulmonary nitric oxide exchange dynamics. J Appl Physiol 85:653- 666, 1998.
22. Lehtimäki L, Kankaanranta H, Saarelainen S, et al. Inhaled fluticasone decreases bronchial but not alveolar nitric oxide output in asthma. Eur Respir J 18:635- 639, 2001.
23. Gelb AF, Moridzadeh R, Singh DH, et al. In moderate-to-severe asthma patients monitoring exhaled nitric oxide during exacerbation is not a good predictor of spirometric response to oral corticosteroid. J Allergy Clin Immunol 129:1491-1498, 2012.
24. Cohen J, Douma WR, ten Hacken NH, et al. Ciclesonide improves measures of small airway involvement in asthma. Eur Respir J 31:1213-1220, 2008.
25. Expert Panel Report 3 (EPR-3): Guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol 120:S94 -S138, 2007.
26. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 26:319 -338, 2005.
27. Gelb AF, Flynn Taylor C, Shinar CM, et al. Role of spirometry and exhaled nitric oxide to predict exacerbations in treated asthmatics. Chest 129:1492-1499, 2006. (Pubitemid 43894977)
28. Tsoukias NM, Shin HW, Wilson AF, and George SC. A single-breath technique with variable flow rate to characterize nitric oxide exchange dynamics in the lungs. J Appl Physiol 91:477-487, 2001. (Pubitemid 32574759)
29. Condorelli P, Shin HW, Aledia AS, et al. A simple technique to characterize proximal and peripheral nitric oxide exchange using constant flow exhalations and an axial diffusion model. J Appl Physiol 102:417- 425, 2007.
30. Gelb AF, Taylor CF, Nussbaum E, et al. Alveolar and airway sites of nitric oxide inflammation in treated asthma. Am J Respir Crit Care Med 170:737-741, 2004. (Pubitemid 39298987)
31. Mahut B, Delacourt C, Zerah-Lancner F, et al. Increase in alveolar nitric oxide in the presence of symptoms in childhood asthma. Chest 125:1012-1018, 2004. (Pubitemid 38367294)
32. Djukanović R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 170:583-593, 2004.
33. van Rensen EL, Evertse CE, van Schadewijk WA, et al. Eosinophils in bronchial mucosa of asthmatics after allergen challenge: Effect of anti-IgE treatment. Allergy 64:72- 80, 2009.
34. Hanania NA, Wenzel S, Rosén K, et al. Exploring the effects of omalizumab in allergic asthma: An analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 187:804-811, 2013.
35. Kharitonov SA, and Barnes PJ. Exhaled markers of pulmonary disease. Am J Respir Crit Care Med 163:1693-1722, 2001. (Pubitemid 32578777)
36. Dupont LJ, Demedts MG, and Verleden GM. Prospective evaluation of the validity of exhaled nitric oxide for the diagnosis of asthma. Chest 123:751-756, 2003. (Pubitemid 36315489)
37. Shaw DE, Berry MA, Thomas M, et al. The use of exhaled nitric oxide to guide asthma management: A randomized controlled trial. Am J Respir Crit Care Med 176:231-237, 2007. (Pubitemid 47195872)
38. Prieto L, Gutiérrez V, Torres V, et al. Effect of salmeterol on seasonal changes in airway responsiveness and exhaled nitric oxide in pollen-sensitive asthmatic subjects. Chest 122:798-805, 2002.
39. Buchvald F, and Bisgaard H. Comparisons of the complementary effect on exhaled nitric oxide of salmeterol vs montelukast in asthmatic children taking regular inhaled budesonide. Ann Allergy Asthma Immunol 91:309 -313, 2003.
40. McGrath KW, Icitovic N, Boushey HA, et al. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med 185:612- 619, 2012.
41. van Veen IH, Sterk PJ, Schot R, et al. Alveolar nitric oxide versus measures of peripheral airway dysfunction in severe asthma. Eur Respir J 27:951-956, 2006. (Pubitemid 44911108)
42. Lehtimäki L, Kankaanranta H, Saarelainen S, et al. Extended exhaled NO measurement differentiates between alveolar and bronchial inflammation. Am J Respir Crit Care Med 163:1557-1561, 2001. (Pubitemid 32578755)
43. Brindicci C, Ito K, Resta O, et al. Exhaled nitric oxide from lung periphery is increased in COPD. Eur Respir J 26:52-59, 2005. (Pubitemid 40945931)
44. Malerba M, Radaeli A, Ragnoli B, et al. Exhaled nitric oxide levels in systemic sclerosis with and without pulmonary involvement. Chest 132:575-580, 2007. (Pubitemid 47282391)
45. Roy K, Borrill ZL, Starkey C, et al. Use of different exhaled nitric oxide multiple flow rate models in COPD. Eur Respir J 29:651-659, 2007. (Pubitemid 46554613)
46. Silkoff PE, Romero FA, Gupta N, et al. Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody. Pediatrics 113:e308-e312, 2004.
47. Fortuna AM, Balleza M, Calaf N, et al. Determining the alveolar component of nitric oxide in exhaled air: Procedures and reference values for healthy persons. Arch Bronconeumol 45:145-149, 2009.
48. Högman M, Lafih J, Meriläinen P, et al. Extended NO analysis in a healthy subgroup of a random sample from a Swedish population. Clin Physiol Funct Imaging 29:18 -23, 2009.
49. Sepponen A, Lehtimäki L, Huhtala H, et al. Alveolar and bronchial nitric oxide output in healthy children. Pediatr Pulmonol 43:1242-1248, 2008.